ONLINE DAT Benzodiazepines II
Enzyme Immunoassay, Benzodiazepine. 510(k) K221765, from Roche Diagnostics (Indianapolis, IN). Product code JXM, class 2.
As of Nov 20, 2026, K221765 is an FDA 510(k) held by Roche Diagnostics, substantially equivalent on Dec 23, 2022 after 189 days, with no recalls tied to it in FDA's recall database.
- Review time: 189 days
- Recalls: 0
Benzodiazepines II (BNZ2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of benzodiazepines in human urine on cobas c systems at cutoff concentrations of 100 ng/mL, 200 ng/mL, and 300 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program.
- Online Dat Benzodiazepines PlusK043327 · Roche Diagnostics Corp. · Feb 7, 2005
- Alinity c Benzodiazepines Reagent KitK243498 · Microgenics Corporation · Dec 11, 2024
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Jun 17, 2022
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3170
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files